GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about TRIUMPH that I am slightly embarrassed to ask — 48 comments in the full submission. View in context.
3.2k
c/trialwatch·submitted 2 years ago by u/joaquin_trevino

genuine question about TRIUMPH that I am slightly embarrassed to ask

Trial Databranch of 8 comments

Trying to get a straight answer on this: genuine question about TRIUMPH that I am slightly embarrassed to ask. Why comparing across trials almost never works, with the specific failure modes. Different populations: an obesity programme and a diabetes programme enrol different people with different baseline…

Read the full submission and all 48 comments →

This branch

8 comments, started 2 years ago
u/milan_villalobos161 points·2 years ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink
u/renal_outcomes_rnephro-curious189 points·2 years ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink
u/yara_mensah65 points·2 years ago

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

replysharereportpermalink
u/ms_fragmenter47 points·2 years ago

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

replysharereportpermalink
u/joaquin_trevinoOP29 points·2 years ago

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

replysharereportpermalink
u/tove_ogunleye6 points·2 years ago

discontinuation rate is a result, not a footnote

replysharereportpermalink
load more comments (2) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →